Trial Profile
Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute. Demonstrative Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2017
Price :
$35
*
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- 08 Aug 2017 New trial record